ReviewRheumatic diseases clinics of North America2021
Recent Updates in Juvenile Spondyloarthritis.
Review in Rheumatic diseases clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis.Arthritis care & research · 2026Review
- Age-Related Microbiota Signatures in Inflammatory Diseases: Comparative Insights into Paediatric and Adult Crohn's Disease, Ulcerative Colitis, and Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
- Juvenile Spondyloarthropathies: Diagnostic and Therapeutic Advances-A Narrative Review.Journal of clinical medicine · 2025Review
- Association of Infant Breastfeeding and Juvenile Spondyloarthritis: A Case-Control Study.The Journal of rheumatology · 2024Article
- Profile of HLA-B27-positive enthesitis/spondylitis-related arthritis in Senegal, West Africa.Pediatric rheumatology online journal · 2024Article
- Seronegative spondyloarthropathy-associated inflammatory bowel disease.World journal of gastroenterology · 2023Review
- Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Juvenile Spondyloarthritis (JSpA): To What Extent Are They Related?Journal of clinical medicine · 2023Article
- Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients.Children (Basel, Switzerland) · 2022Article
- Editorial: Juvenile Spondyloarthritis: From Basic Science to Clinical Translation.Frontiers in medicine · 2022Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Spondyloarthritis represents a group of disorders characterized by enthesitis and axial skeletal involvement. Juvenile spondyloarthritis begins before age 16. Joint involvement is usually asymmetric. Bone marrow edema on noncontrast MRI of the sacroiliac joints can facilitate diagnosis. The most significant risk factor for axial disease is HLA-B27. Most patients have active disease into adulthood. Enthesitis and sacroiliitis correlate with greater pain intensity and poor quality-of-life measures. Tumor necrosis factor inhibitors are the mainstay of biologic therapy. Although other biologics such as IL-17 blockers have shown benefit in adult spondyloarthritis, none are approved by the US Food and Drug Administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.